Radius falters after a PhIII osteoporosis fail and a breast cancer disappointment, sending shares plummeting

Max Gelman

Senior Editor

Radius Health saw shares tank on Wednesday after reporting two Phase III study results, one for an osteoporosis patch treatment that failed and one for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Radius falters after a PhIII osteoporosis fail and a breast cancer disappointment, sending shares plummeting

Max Gelman

Senior Editor

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

As bluebird projects more commercial demand, the biotech continues to seek cash

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Ra­dius fal­ters af­ter a PhI­II os­teo­poro­sis fail and a breast can­cer dis­ap­point­ment, send­ing shares plum­met­ing

Max Gelman

Senior Editor

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Radius falters after a PhIII osteoporosis fail and a breast cancer disappointment, sending shares plummeting

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

As bluebird projects more commercial demand, the biotech continues to seek cash

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?